Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $28,000.

  • Cidara Therapeutics' Depreciation & Amortization (CF) fell 31.71% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $177,000, marking a year-over-year increase of 20.41%. This contributed to the annual value of $200,000 for FY2024, which is 78.57% up from last year.
  • Per Cidara Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $28,000 for Q3 2025, which was up 3.70% from $27,000 recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Depreciation & Amortization (CF) ranged from a high of $86,000 in Q4 2024 and a low of $22,000 during Q3 2023.
  • In the last 3 years, Cidara Therapeutics' Depreciation & Amortization (CF) had a median value of $33,000 in 2023 and averaged $36,636.
  • In the last 5 years, Cidara Therapeutics' Depreciation & Amortization (CF) crashed by 40.79% in 2021 and then surged by 160.61% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $48,000 in 2021, then slumped by 39.58% to $29,000 in 2022, then grew by 13.79% to $33,000 in 2023, then spiked by 160.61% to $86,000 in 2024, then crashed by 31.71% to $28,000 in 2025.
  • Its Depreciation & Amortization (CF) was $28,000 in Q3 2025, compared to $27,000 in Q2 2025 and $36,000 in Q1 2025.